A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting

Background Daratumumab is used in the treatment of relapsed multiple myeloma. Daratumumab infusion-related reactions can occur with the highest incidence on the first infusion. Methods A retrospective review of all daratumumab infusions used as part of the DVd and DRd regimens for relapsed multiple...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2021-06, Vol.27 (4), p.907-910
Main Authors: Geirnaert, Marc, Howarth, Jacy, Martin, Kristen, Ricard, Chad, Streilein, Scott, Wasney, Danica, Dao, Vi, Kotb, Rami, Rimmer, Emily, Minuk, Leonard
Format: Article
Language:English
Subjects:
Clinical trials
Immunotherapy
Monoclonal antibodies
Multiple myeloma
Patients
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Daratumumab is used in the treatment of relapsed multiple myeloma. Daratumumab infusion-related reactions can occur with the highest incidence on the first infusion. Methods A retrospective review of all daratumumab infusions used as part of the DVd and DRd regimens for relapsed multiple myeloma was undertaken. The review of infusion-related reactions was conducted by reviewing the treatment room nursing note on the days that daratumumab was administered. If the patient experienced an infusion-related reaction, then the data captured included if the full dose was administered. Results Daratumumab infusion-related reactions occurred most frequently on the first dose. The rates of infusion-related reactions using a split dose approach for daratumumab administration were lower than that reported in clinical trials. All of the infusion-related reactions were managed with appropriate interventions in the outpatient setting. The adoption of rapid infusion daratumumab beginning with cycle 2 of DVd and DRd was well tolerated. Conclusions Our experience of daratumumab infusions using a split dose approach was associated with an infusion-related reaction rate in 28% of patients on cycle 1, day 1 of DVd and DRd regimens. All patients were able to complete full doses of daratumumab by utilizing split dose. The rates of daratumumab infusion-related reactions are highest on the first infusion. In addition, our adoption of rapid infusion daratumumab was safe.
ISSN:1078-1552
1477-092X
DOI:10.1177/1078155220967738